Skip to main content
  • COVID-19
    • COVID-19 vaccines and cancer
      • FAQs
      • FAQs in-language
      • SerOzNET Study
    • COVID-19 information for people affected by cancer
      • Managing your cancer care in the context of COVID-19
      • Looking after your mental wellbeing
      • Canada
      • Ireland
      • UK
      • USA
    • COVID-19 information for children and young people with cancer
    • Cancer Won’t Wait
    • Cancer and COVID-19 - what it means for our Mob
      • COVID-19 vaccines: Information for Aboriginal and Torres Strait Islander people affected by cancer
      • Act early for our Mob's health
    • Guidance for health professionals
      • Diagnosis
      • Treatment
      • Surgery
      • Medical oncology
      • Radiation oncology
      • Primary care
      • Telehealth
      • Clinical trials
      • Follow-up care
      • Supportive and Palliative care
      • Cancer care for cancer patients with COVID-19
      • COVID-19 vaccines and cancer
      • Recovery
    • Research articles
      • Review articles
      • Data articles
      • Recommendations articles
      • Shared experience articles
      • COVID-19 vaccines and cancer articles
    • Cancer care in the time of COVID-19: A conceptual framework
    • Optimal cancer care during the COVID-19 pandemic: the Principles
    • The impact of COVID-19 on cancer services
    • COVID-19 Recovery: Implications for cancer care
      • Expanded use of telehealth
      • Changes to prevention and early detection
      • Virtual multidisciplinary team meetings
      • Modifications to treatment schedules
      • Hypofractionated radiotherapy
      • Oncology hospital in the home
      • Responsive patient support
      • Innovative care and hospital infrastructure models
      • Shared follow-up and survivorship care
      • Supportive and palliative care
      • Cancer research and clinical trials
      • Collaboration in the oncology sector and data sharing
      • Acknowledgements
  • About us
    • Organisational structure
    • Accountability and reporting
      • Annual reports
    • Who we work with
      • Roles & functions
      • Advisory Council
      • Advisory groups
      • Consumer engagement
      • Government cancer control organisations
    • Information publication scheme
      • Information publication scheme plan
      • Freedom of information act
        • The FOI request process
      • FOI disclosure log
    • Reconciliation action plan
    • Employment opportunities
  • News and media
    • News
    • Subscribe to our eNewsletter
  • Contact us
Cancer Australia
Choose Language
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • Home
  • Cancer types
  • Impacted by Cancer
  • Awareness
  • Research
  • Resources
  • Clinicians hub
  • Key initiatives
  • Home
  • Cancer types
    • Bladder cancer
    • Bowel cancer
    • Brain cancer
    • Breast cancer
    • Breast cancer in men
    • Breast cancer in young women
    • Cervical cancer
    • Children’s cancer
    • Endometrial cancer
    • Fallopian cancer
    • Gestational trophoblastic disease
    • Gynaecological cancers
    • Head and neck cancer
    • Kidney cancer
    • Leukaemia
    • Liver cancer
    • Lung cancer
    • Lymphoma
    • Melanoma
    • Mesothelioma cancer
    • Myeloma
    • Neuroendocrine tumours
    • Oesophageal cancer
    • Ovarian cancer
    • Pancreatic cancer
    • Prostate cancer
    • Sarcoma
    • Stomach cancer
    • Testicular cancer
    • Thyroid cancer
    • Unknown primary cancer
    • Uterine sarcoma
    • Vaginal cancer
    • Vulvar cancer
  • Impacted by Cancer
    • What is cancer
    • Physical changes
    • Treatment
    • Keeping healthy
    • Emotions
    • Family and relationships
    • Living with cancer
    • Lynch Syndrome
  • Awareness
    • Your cancer risk
    • Screening
    • Interactive body map
  • Research
    • Cancer Research in Australia
    • Data and statistics
    • Australian Clinical Trials
    • Support for cancer clinical trials
    • Grants and funding
  • Resources
    • Cancer Australia Publications
    • Clinical Practice Guidelines
    • Position statements
    • Resources in other languages
    • Cancer Australia websites
    • Cancer risk online assessment tools
    • Other tools and resources
    • Podcasts
    • Cancer support organisations
    • Glossary
  • Clinicians hub
    • GP guides and resources
    • Guidelines by cancer type
    • Optimal Care pathways
    • Working with Aboriginal and Torres Strait Islander people
    • Multidisciplinary care
    • Psychosocial care
    • Follow-up care
    • Family cancer clinics
    • Cancer Learning
    • Consumer engagement
  • Key initiatives
    • For Aboriginal and Torres Strait Islander people
    • Australian Cancer Plan
    • Australian Brain Cancer Mission
    • Lung Cancer Screening
    • National Pancreatic Cancer Roadmap
    • Campaigns & events
    • Jeannie Ferris Recognition Award

Melanoma of the skin

melanoma-mm cancer-types/melanoma/overview
    • Home
    • Types
    • Statistics
    • Risk factors
    • Symptoms
    • Diagnosis
    • Treatment
    • Finding support
    • Clinical trials
    • Health professionals
    • Home
    • Types
    • Statistics
    • Risk factors
    • Symptoms
    • Diagnosis
    • Treatment
    • Finding support
    • Clinical trials
    • Health professionals
  1. Home
  2. Statistics
Loading...

Melanoma of the skin statistics

  • Printer-friendly version
  • A|A

The following material has been sourced from the Australian Institute of Health and Welfare

Melanoma skin cancer incorporates ICD-10 cancer code C43 (Malignant neoplasm of skin).


Estimated number of new cases of melanoma of the skin diagnosed in 2022

17,756 = Male icon PNG 10,374 males + Female icon PNG 7,382 females


Estimated % of all new cancer cases diagnosed in 2022

11%


Estimated number of deaths from melanoma of the skin in 2022

1,281 =  Male icon PNG 825 males + Female icon PNG 456 females


Estimated % of all deaths from cancer in 2022

2.6%


Chance of surviving at least 5 years (2014–2018)

93%


People living with melanoma of the skin at the end of 2017 (diagnosed in the 5 year period 2013 to 2017)

62,881


New cases

Melanoma of the skin was the fourth most commonly diagnosed cancer in Australia in 2018. It is estimated that it will become the third most commonly diagnosed cancer in 2022.

In 2018, there were 15,346 new cases of melanoma of the skin diagnosed in Australia (8,941 males and 6,403 females). In 2022, it is estimated that 17,756 new cases of melanoma of the skin will be diagnosed in Australia (10,374 males and 7,382 females). In 2022, it is estimated that a person has a 1 in 17 (or 5.8%) risk of being diagnosed with melanoma of the skin by the age of 85 (1 in 14 or 6.9% for males and 1 in 21 or 4.7% for females).

 

Figure 1. Estimated cancer incidence in Australia, 2022

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about incidence rates for the most common cancers diagnosed can be found on the NCCI website in the ‘Cancer incidence’ section (https://ncci.canceraustralia.gov.au/diagnosis/cancer-incidence/cancer-incidence) 

In 2018, the age-standardised incidence rate was 54 cases per 100,000 persons (66 for males and 44 for females). In 2022, it is estimated that the age-standardised incidence rate will be 57 cases per 100,000 persons (69 for males and 47 for females). The incidence rate for melanoma of the skin is expected to increase with age, highest for those aged 85–89 years.

Figure 2. Age-standardised incidence rates for melanoma of the skin, 1982 to 2018, by sex

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about incidence rates for melanoma skin cancer over time, by age, sex, Indigenous status, remoteness, and socioeconomic status (SES) can be found on the NCCI website in the ‘Cancer incidence’ section (https://ncci.canceraustralia.gov.au/diagnosis/cancer-incidence/cancer-incidence) 

The number of new cases of melanoma of the skin diagnosed increased from 3,541 (1,738 males and 1,803 females) in 1982 to 15,346 in 2018. Over the same period, the age-standardised incidence rate increased from 27 cases per 100,000 persons (28 for males and 26 for females) in 1982 to 54 cases per 100,000 in 2018.

Deaths 

In 2020, melanoma of the skin was the tenth most common cause of cancer death in Australia. It is estimated that it will become the eleventh most common cause of death from cancer in 2022.

In 2020, there were 1,401 deaths from melanoma of the skin in Australia (939 males and 462 females). In 2022, it is estimated that there will be 1,281 deaths (825 males and 456 females). In 2022, it is estimated that a person has a 1 in 265 (or 0.38%) risk of dying from melanoma of the skin by the age of 85 (1 in 204 or 0.49% for males and 1 in 383 or 0.26% for females).

Figure 3. Estimated cancer mortality in Australia, 2022

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about mortality rates for the most common causes of cancer death can be found on the NCCI website in the ‘Cancer mortality’ section (https://ncci.canceraustralia.gov.au/outcomes/cancer-mortality/cancer-mortality) 

In 2020, the age-standardised mortality rate was 4.3 deaths per 100,000 persons (6.4 for males and 2.6 for females). In 2022, it is estimated that the age-standardised mortality rate will be 3.7 deaths per 100,000 persons (5.2 for males and 2.4 for females). The mortality rate for melanoma of the skin is expected to increase with age.

Mortality rates for melanoma

Figure 4. Age-standardised mortality rates for melanoma of the skin, 1982 to 2020, by sex

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about mortality rates for melanoma skin cancer over time, by age, sex, Indigenous status, remoteness, and socioeconomic status (SES) can be found on the NCCI website in the ‘Cancer mortality’ section (https://ncci.canceraustralia.gov.au/outcomes/cancer-mortality/cancer-mortality) 

The number of deaths from melanoma of the skin increased from 596 (380 males and 216 females) in 1982 to 1,401 in 2020. Over the same period, the age-standardised mortality rate remained similar from 4.7 deaths per 100,000 persons (6.4 for males and 3.2 for females) in 1982 to 4.3 deaths per 100,000 in 2020. 

Survival 

In 2014–2018, individuals diagnosed with melanoma of the skin had a 93% chance (92% for males and 95% for females) of surviving for five years compared to their counterparts in the general Australian population. Between 1989–1993 and 2014–2018, five-year relative survival for melanoma of the skin improved from 90% to 93%. 

Figure 5. 5-year relative survival for melanoma of the skin, 1989–1993 to 2014–2018, by sex

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about 5-year relative survival rates for melanoma skin cancer over time, by age, sex, Indigenous status, remoteness, and socioeconomic status (SES) can be found on the NCCI website in the ‘Relative survival rate’ section (https://ncci.canceraustralia.gov.au/outcomes/relative-survival-rate/5-year-relative-survival) 

Prevalence 

At the end of 2017, there were 14,584 people living who had been diagnosed with melanoma of the skin that year, 62,881 people living who had been diagnosed with melanoma of the skin in the previous 5 years (from 2013 to 2017) and 207,943 people living who had been diagnosed with melanoma of the skin in the previous 36 years (from 1982 to 2017).

For more information, see Melanoma skin cancer on the NCCI website 

The National Cancer Control Indicators (NCCI) are a set of indicators across the continuum of cancer care, from Prevention and Screening through to Diagnosis, Treatment, Psychosocial care, Research and Outcomes.  The NCCI website allows users to see visual representations of data on each indicator through interactive charts.

  • Last Updated
  • Relevant Links
updated: 15 September 2022 - 10:06am
Cancer Council Australia, Melanoma
National Cancer Institute (US)
American Cancer Society

Related information

What is cancer?
What is cancer?

Cancer is a disease of the cells, which are the body’s basic building blocks.

Treatment and side effects
Treatment and side effects

The treatment that your doctors recommend will depend on the type of cancer you have, how advanced it is, and other personal factors.

Living with cancer
Living with cancer

A diagnosis of cancer marks the beginning of a journey full of emotional, psychological, physical and practical challenges.

Life after cancer
Life after cancer

While looking forward to finishing their cancer treatment and getting on with life, for some people, the end of treatment can also be a confusing or worrying time.

A-Z List of Cancer Types

Information on more than 70 types of cancer

  • Bladder cancer
  • Bowel cancer
  • Brain cancer
  • Breast cancer
  • Breast cancer in men
  • Breast cancer in young women
  • Cervical cancer
  • Children's Cancer
  • Endometrial cancer
  • Fallopian cancer
  • Gestational trophoblastic disease
  • Gynaecological cancers
  • Head and neck cancer
  • Kidney cancer
  • Leukaemia
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Melanoma of the skin
  • Mesothelioma cancer
  • Myeloma
  • Neuroendocrine tumours
  • Oesophageal cancer
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
  • Sarcoma
  • Stomach cancer
  • Testicular cancer
  • Thyroid cancer
  • Unknown primary
  • Uterine sarcoma
  • Vaginal cancer
  • Vulval cancer

About Cancer Australia

Cancer Australia was established by the Australian Government in 2006 to benefit all Australians affected by cancer, and their families and carers. Cancer Australia aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer by leading and coordinating national, evidence-based interventions across the continuum of care.

If you would like an interpreter to help you understand any information on this website, please call TIS National on 131 450 and ask them to call Cancer Australia on 02 9357 9400. Our business hours are 9am to 5pm, Monday to Friday.

Freecall 1800 624 973
+61 2 9357 9400

Locked Bag 3, Strawberry Hills
NSW 2012

Navigation

  • Cancer types
  • Impacted by Cancer
  • Awareness
  • Research
  • Resources
  • Clinicians hub
  • Key initiatives

Contact us

* Denotes mandatory fields
 

By submitting this form, you accept the Cancer Australia privacy policy.

  • Contact Us
  • Copyright
  • Disclaimer
  • Privacy policy
  • Sitemap
Copyright © 2023 - Cancer Australia